Supply / Manufacturing · Latin America · Announced 10 Feb 2026

Moderna → Government of Mexico / BIRMEX

Moderna signed a five-year MoU with the Government of Mexico and state laboratory BIRMEX to supply its respiratory vaccines, with local clinical R&D and pandemic preparedness, after a government award of up to 10 million COVID-19 doses.

Parties: Moderna (United States) → Government of Mexico / BIRMEX (Mexico)

Value
Undisclosed
Territory
Mexico
Therapeutic area
Vaccines
Assets
Spikevax; respiratory vaccine portfolio
Announced
10 Feb 2026

Our analysis

Why this matters

On 10 February 2026, Moderna signed a five-year memorandum of understanding with the Government of Mexico and Laboratorios de Biológicos y Reactivos de México (BIRMEX), the federally owned biologics laboratory, to supply its respiratory vaccine portfolio in Mexico. The pact also covers local clinical research and pandemic-preparedness collaboration, and runs alongside a technology transfer to Laboratorios Liomont for the COVID-19 vaccine mRNA-1273. Financial terms were not disclosed.

The MoU follows COFEPRIS approval of Moderna's 2025–2026 COVID-19 vaccine for people aged six months and older, and a government purchase of up to 10 million doses awarded to Medistik (Logística y Transporte para la Industria de la Salud). Moderna's CEO linked the deal to "growing demand for these vaccines in Mexico" and to sales growth "through geographic diversification".

The full analysis is free to read with a work email on this page.

Source: Moderna press release (ACCESS Newswire via Nasdaq); Fierce Pharma; Mexico Business News

Latest deals

All Latin America deals → · All supply / manufacturing deals → · Browse all emerging-market pharma deals →